<DOC>
	<DOC>NCT02452372</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and tolerability of ALN-AS1 in AIP patients as well as to characterize pharmacokinetics (PK) and pharmacodynamics (PD) of ALN-AS1 in AIP patients.</brief_summary>
	<brief_title>A Phase 1 Study of ALN-AS1 in Patients With Acute Intermittent Porphyria (AIP)</brief_title>
	<detailed_description />
	<mesh_term>Porphyrias</mesh_term>
	<mesh_term>Porphyria, Erythropoietic</mesh_term>
	<mesh_term>Porphyria, Acute Intermittent</mesh_term>
	<criteria>Parts A and B Diagnosis of AIP Urine PBG at Screening indicating patient is a high excreter No clinically significant health concerns Women of child bearing potential must have a negative pregnancy test, not be nursing, and use effective contraception Willing to provide written informed consent and willing to comply with study requirements. Porphyria attack within 6 months of screening Started a new prescription medication within 3 months of screening Clinically significant abnormal laboratory results Received an investigational agent within 90 days before the first dose of study drug or are in followup of another clinical study History of multiple drug allergies or intolerance to subcutaneous injection Part C Diagnosis of AIP Patient experienced a porphyria attack or was taking medication to prevent attacks recently No clinically significant health concerns Women of child bearing potential must have a negative pregnancy test, not be nursing, and use effective contraception Willing to provide written informed consent and willing to comply with study requirements. Stared a new prescription medication within 3 months of screening Clinically significant abnormal laboratory results Received an investigational agent within 90 days before the first dose of study drug or are in followup of another clinical study History of multiple drug allergies or intolerance to subcutaneous injection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>RNAi therapeutic</keyword>
	<keyword>Porphyria</keyword>
	<keyword>AIP</keyword>
</DOC>